Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen
复制标题
DOI：
10.1038/sj.bjc.6600553
复制
发表时间：
2002-10-07
影响因子：
8.8
通讯作者：
Slevin, ML
中科院分区：
文献类型：
--
作者：
Slater, S;Shamash, J;Slevin, ML
伊立替康、丝裂霉素和顺铂在胃食管癌中均显示出活性。这种新颖的组合在28天的周期内被用于以前未经治疗的不能手术的胃食管癌或胰腺癌的门诊患者。31名胃食管癌患者中有26名和14名胰腺癌患者中有12名接受了这种联合治疗，并可评估疗效。胃食管癌患者的总有效率为42%，中位生存期为9.5个月。在胰腺癌患者中，总有效率为42%，中位生存期为8个月。在达到稳定疾病反应的患者和达到部分反应或完全反应的患者之间，有统计学上显著的生存增加。两种癌症的毒性特征几乎相同。有5例治疗相关死亡，住院率高（42%）。因此，伊立替康、丝裂霉素和顺铂是治疗不能手术的上胃食管癌的新组合，但具有较高的毒性。未来的发展包括将伊立替康的剂量和治疗周期减少到4个。(C) 2002年英国癌症研究中心。
Irinotecan, mitomycin and cisplatin all demonstrate activity in gastro-oesophageal cancers. This novel combination was administered to outpatients with previously untreated inoperable gastro-oesophageal or pancreatic cancer, in a 28-day cycle. A total of 26 out of 31 patients with gastro-oesophageal cancer and 12 out of 14 patients with pancreatic cancer have been treated with this combination, and were evaluable for response. The overall response rates for patients with gastro-oesophageal cancer was 42%, with a median survival of 9.5 months. In patients with pancreatic cancer, the overall response rate was 42% with a median survival of 8 months. There was a statistically significant increase in survival between those patients who achieved a stable disease response and those who achieved either a partial response or complete response. The toxicity profiles for both cancers were virtually identical. There were five treatment-related deaths, and a high admission rate (42%). Thus irinotecan, mitomycin and cisplatin is a new combination with activity in inoperable upper gastro-oesophageal cancers, but with a high toxicity profile. Future developments include reducing the dose of irinotecan and number of cycles of therapy to four. (C) 2002 Cancer Research UK.